Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Pazopanib, Atc L01ex03 For The Period January 1st, 2026 - December 31st, 2027 (plus Extension Option 1x12 Months) 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Tildrakizumab, Atc L04ac17 For The Period January 1st, 2026 - December 31st, 2027 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Insulin Lispro, Atc A10ab04 And A10ad04 For The Period January 1st, 2026 - December 31st, 2027 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Pazopanib, Atc L01ex03 For The Period 01.01.2026 - 31.12.2027 (plus Extension Option 1x12 Months) Pazopanib 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Buserelin, Atc L02ae01 For The Period January 1st, 2026 - December 31st, 2027 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement For The Active Ingredient Insulin Lispro For The Period From January 1, 2026, To December 31, 2027. Insulin Lispro 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Peginterferon Beta-1a For The Period From 01.01.2026 To 31.12.2027. Peginterferon Beta-1a 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Guanfacin For The Period 01.01.2026 - 31.12.2027 (plus Extension Option 1x12 Months). Guanfacin 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Lebrikizumab, Atc D11ah10 For The Period January 1st, 2026 - December 31st, 2027 2026-05-16
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Tildrakizumab, Atc L04ac17 For The Period January 1st, 2026 - December 31st, 2027 2026-05-16
Whats app